Clinic
Legacy Mount Hood Medical Center
Legacy Mount Hood Medical Center was paid $43.16M by Medicaid between Jan 2018 and Dec 2024, across 105 billing codes. Its largest line is 99284, emergency room visit (serious) — 28% of everything it billed.
33Billing provider infoLEGACY MOUNT HOOD MEDICAL CENTER
GRESHAM, OR 97030
GRESHAM, OR 97030
33aNPI1255354700assigned 07/25/2006
33bProvider typeClinic/Center
28Total paid$43.16M
24GClaims513,568
24DCodes billed105
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Oregon
Rank by total paid#1 of 167
Median peer was paid$141K
This provider vs. median307×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JENSEN, SARAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 70,537 | $4.43M | |
| 2019 | 68,238 | $5.41M | |
| 2020 | 61,569 | $5.14M | |
| 2021 | 64,300 | $5.41M | |
| 2022 | 85,706 | $6.87M | |
| 2023 | 86,724 | $7.98M | |
| 2024incomplete | 76,494 | $7.91M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 48,306 | 45,241 | $12.22M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 26% | 34,142 | 31,599 | $11.31M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 58,325 | 54,851 | $10.25M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 8.4% | 27,659 | 25,678 | $3.61M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 9,524 | 8,371 | $915K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.8% | 1,929 | 1,854 | $759K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 7,394 | 7,054 | $676K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 14,293 | 13,134 | $539K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 8,880 | 7,983 | $505K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,350 | 7,686 | $368K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,614 | 3,907 | $322K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 489 | 466 | $302K |
93 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,106 | $257K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,750 | $201K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 310 | $173K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,694 | $141K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,020 | $114K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 875 | $101K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 153 | $86K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 394 | $74K |
| 95811 | <1% | 95 | $46K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 228 | $30K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 27,893 | $24K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 220 | $21K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,217 | $20K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 199 | $14K |
| 80053 | Comprehensive metabolic panel | <1% | 44,302 | $12K |
| 87631 | <1% | 1,617 | $8K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 15 | $7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 691 | $7K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 56,566 | $7K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $4K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 128 | $4K |
| 82947 | <1% | 2,128 | $3K | |
| 84703 | <1% | 18,376 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 559 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 13 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,403 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 66 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 65 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 66 | $1K |
| 83690 | <1% | 12,643 | $1K | |
| 93308 | <1% | 78 | $1K | |
| 94060 | <1% | 45 | $743.22 | |
| 81003 | <1% | 18,843 | $715.23 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,210 | $710.00 |
| 93272 | <1% | 40 | $702.83 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 268 | $560.00 |
| 84484 | <1% | 11,225 | $508.80 | |
| 99442 | <1% | 29 | $506.16 | |
| 73630 | <1% | 45 | $473.50 | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,272 | $464.36 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,446 | $330.45 |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,862 | $308.61 |
| 36592 | <1% | 43 | $297.38 | |
| 81001 | <1% | 5,587 | $245.36 | |
| 93321 | <1% | 78 | $244.01 | |
| 85027 | <1% | 3,598 | $178.62 | |
| 94726 | <1% | 29 | $174.68 | |
| 94729 | <1% | 32 | $140.70 | |
| 87430 | <1% | 410 | $132.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,779 | $69.49 |
| J3490 | Unclassified drugs | <1% | 377 | $64.16 |
| A9270 | Non-covered item or service | <1% | 240 | $55.30 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,611 | $37.41 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 329 | $31.87 |
| 80076 | <1% | 280 | $12.00 | |
| 85379 | <1% | 121 | $8.14 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,065 | $7.20 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 132 | $5.25 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 397 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 62 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 54 | $0.00 |
| 80299 | 0% | 44 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 13 | $0.00 |
| 80143 | 0% | 74 | $0.00 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 14 | $0.00 |
| 73562 | 0% | 55 | $0.00 | |
| 85610 | 0% | 63 | $0.00 | |
| 80179 | 0% | 73 | $0.00 | |
| 72100 | 0% | 13 | $0.00 | |
| 87210 | 0% | 12 | $0.00 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 12 | $0.00 |
| 83605 | 0% | 28 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 247 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 197 | $0.00 |
| 82077 | 0% | 437 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 286 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 259 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 26 | $0.00 |
| 83735 | 0% | 728 | $0.00 | |
| 36416 | 0% | 179 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 76 | $0.00 |
| 83880 | 0% | 55 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 87 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 72 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 14 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 99 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 12 | $0.00 |
| 87070 | 0% | 12 | $0.00 | |
| 88342 | 0% | 12 | $0.00 | |
| G0378 | Hospital observation service, per hour | 0% | 16 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 12 | $0.00 |
| 85730 | 0% | 15 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJENSEN, SARAH (VP FINANCE)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.